Compare Build A Bear Workshop Inc (BBW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Build A Bear Workshop Inc vs TG Therapeutics Inc — how do they compare? Build A Bear Workshop Inc trades at $37.21 (market cap $461.88M), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 16.5× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.5% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BBW | TGTX | |
|---|---|---|
Market Cap | $461.88M | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $75.85 | $59.06 |
52-Week Low | $29.84 | $26.94 |
Enterprise Value | $561.32M | $7.84B |
Dividend Yield | 2.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBW trades at $36.98, down 0.75% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 10.48% net income margin and 35.87% ROE, while valuation ratios like a P/E of 8.63 suggest potential undervaluation. Recent earnings beats and a new CEO transition highlight operational strength, though Q1 2026 revenue dipped 2.4% year-over-year amid consumer caution.
The outlook is positive with a consensus price target of $62.50 implying significant upside, driven by international expansion and a debt-free balance sheet. Risks include near-term inflation headwinds and competitive pressures, but analyst sentiment remains strongly bullish with 73% buy ratings, positioning BBW for recovery in the latter half of 2026.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Build A Bear Workshop Inc
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
